PRODUCT MONOGRAPH
PRODUCT MONOGRAPH DUKORAL® Oral, Inactivated Cholera and ETEC Diarrhea Vaccine Oral Suspension Active Immunizing Agent for the Prevention of Diarrhea Caused by Vibrio cholerae and/or heat-labile toxin producing Enterotoxigenic Escherichia coli ATC Code: J07AE01 Manufactured by: Date of Approval: Valneva Sweden AB,
Download PRODUCT MONOGRAPH
Information
Domain:
Source:
Link to this page:
Documents from same domain
PRESCRIBING INFORMATION CYANOCOBALAMIN INJECTION, …
pdf.hres.caSupplied: Each ml contains: Cyanocobalamin 1,000 mcg, Sodium Acetate 0.5 mg, Glacial Acetic Acid 0.1 mg, Sodium Chloride 9.0 mg with Benzyl Alcohol 1.5 % as preservative in Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid may have been used to adjust pH . Multiple dose vials of 10 ml and 30mL.
FLUZONE High-Dose Quadrivalent
pdf.hres.casodium chloride solution. - traces of formaldehyde and ovalbumin. ... Quadrivalent does not contain latex (natural rubber). ... (Split Virion)] is a sterile aqueous suspension of inactivated influenza virus for intramuscular injection.
PRODUCT MONOGRAPH
pdf.hres.caPRODUCT MONOGRAPH Pr WELLBUTRIN ... incidence in clinical trials with doses of 450 mg/day was approximately 0.39% (2 of 537 subjects). There were no seizures in clinical trials where subjects (n=1638) were treated up to the maximum recommended dose of 300 mg/day. In post marketing data however, seizures have been observed across all doses and
FLUZONE Quadrivalent
pdf.hres.caSanofi Pasteur Product Monograph 450/477 - FLUZONE® Quadrivalent Page 4 of 35 FLUZONE® Quadrivalent Influenza Virus Vaccine Quadrivalent Types A and B (Split Virion) PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration: Intramuscular injection. Dosage Form/Strength: Suspension for injection.
PRODUCT MONOGRAPH INCLUDING PATIENT …
pdf.hres.caAFLURIA® TETRA (Inactivated Influenza Vaccine (Split Virion)) Product Monograph Page 1 of 24 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION AFLURIA® TETRA Quadrivalent Inactivated Influenza Vaccine (Split Virion) Suspension for Injection Active Immunizing Agent for the Prevention of Influenza ATC Code: J07BB02 2020 - 2021 Strains:
PRODUCT MONOGRAPH
pdf.hres.ca8.4 Post Market Adverse Reactions Table updated to as per the ... is a biosimilar biologic drug (biosimilar) to HERCEPTIN®. PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS Indications have been granted on the basis of similarity between OGIVRI and the reference biologic drug ... OGIVRI (trastuzumab) can result in the development of ...
doses of 0.3 mL) Active Immunizing Agent Mainz, Rhineland ...
pdf.hres.cacomirnaty (covid-19 vaccine, mrna) product monograph page 2 of 53 recent major label changes 1. indications 11/2021 4. dosage and administration 11/2021 7. warnings and precautions 11/2021 table of contents
PRODUCT MONOGRAPH GRAVOL
pdf.hres.caEar/Nose/Throat Dimenhydrinate may mask the presence of underlying organic abnormalities or the toxic effects of certain antibiotics and other drugs, particularly those drugs causing ototoxicity. Endocrine and Metabolism Use with caution in patients who are poor CYP2D6 metabolizers and in patients with thyroid dysfunction. Gastrointestinal
ENGERIX-B
pdf.hres.caPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ENGERIX-B Hepatitis B vaccine (recombinant) 0.5 mL and 1.0 mL suspensions of 20 mcg/mL hepatitis B surface antigen for injection Active immunizing agent against infection caused by all known subtypes of hepatitis B virus ATC Code: J07BC01 GlaxoSmithKline Inc. 7333 Mississauga Road
FLULAVAL TETRA (2021-2022)
pdf.hres.caEgg proteins, sodium deoxycholate, ethanol, formaldehyde, sucrose, -tocopheryl hydrogen succinate, polysorbate 80. Thimerosal preservative in the multidose presentation only. For a complete listing see Dosage Forms, Composition and Packaging section. *The prefilled syringe presentation is not available for the 2021- 2 season DESCRIPTION
Related documents
MATERIAL SAFETY DATA SHEET 1. Product and Company ...
www.rbnainfo.comMar 26, 2010 · Isopropanol 67-63-0 Monograph 71 [1999]; Supplement 7 [1987]; Monograph 15 [1977] Carcinogenicity The finished product is not expected to have chronic health effects. space Mutagenicity The finished product is not expected to have chronic health effects. space Reproductive effects The finished product is not expected to have chronic health ...
PRODUCT MONOGRAPH
pdf.hres.caPRODUCT MONOGRAPH Pr WELLBUTRIN ... PART III: CONSUMER INFORMATION ... symptoms including delusions, hallucinations, psychosis, concentration disturbance, paranoia and confusion. In some cases these abated upon dose reduction and/or withdrawal of treatment.
Fluzone High Dose - Sanofi
products.sanofi.caSanofi Pasteur Product Monograph 372 - FLUZONE® High-Dose Page 3 of 23 FLUZONE® High-Dose Influenza Virus Vaccine Trivalent Types A and B (Split Virion) PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration: Intramuscular injection. Dosage Form/Strength: Suspension for injection. Active …
Forxiga Consumer Information - AstraZeneca
www.astrazeneca.caProduct Monograph Master Template Template date: September 2020 FORXIGA (dapagliflozin propanediol monohydrate) Page 3 of 8 COPYRIGHT 2014-2021 ASTRAZENECA CANADA INC FORXIGA and when to start taking it again. have a sudden reduction in your insulin dose have a history of DKA. • are older than 65 years of age
PRODUCT MONOGRAPH SYMBICORT …
www.astrazeneca.caindicated for the maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema, in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate. SYMBICORTTURBUHALER is NOT indicated for the relief of acute bronchospasm in COPD patients.
PART III: CONSUMER INFORMATION INSPIOLTO RESPIMAT …
www.boehringer-ingelheim.caInspiolto® Respimat ® Product Monograph Page 43 of 50 PART III: CONSUMER INFORMATION ... CONSUMER INFORMATION . ... including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines. ...
PRODUCT MONOGRAPH - Pfizer Canada
www.pfizer.caPrevnar® 13 (Pneumococcal 13-valent Conjugate Vaccine) Product Monograph Page 7of 61 3. Adults 18Years and Older Safety was assessed in 7 clinical studies including 91,593 adults ranging in ages from 18 to 101 years. Prevnar 13 was administered to 48,806 adults; 2,616 adults were aged 50-64 years and 45,291 adults were 65 years and older.
Labeling <7> Type of Posting Posting Date Official Date ...
www.uspnf.comAug 30, 2019 · , Monograph Naming Policy for Salt Drug Substances in Drug Products and Compounded Preparations). Labeling The labeling clearly states the specific salt form of the active moiety that is present in the product or preparation because this information may be useful to practitioners and patients. The names and strengths of both the active moiety ...